TY  - JOUR
AU  - Fortner, Renée T
AU  - Schock, Helena
AU  - Le Cornet, Charlotte
AU  - Hüsing, Anika
AU  - Vitonis, Allison F
AU  - Johnson, Theron S
AU  - Fichorova, Raina N
AU  - Fashemi, Titilayo
AU  - Yamamoto, Hidemi S
AU  - Tjønneland, Anne
AU  - Hansen, Louise
AU  - Overvad, Kim
AU  - Boutron-Ruault, Marie-Christine
AU  - Kvaskoff, Marina
AU  - Severi, Gianluca
AU  - Boeing, Heiner
AU  - Trichopoulou, Antonia
AU  - Papatesta, Eleni-Maria
AU  - La Vecchia, Carlo
AU  - Palli, Domenico
AU  - Sieri, Sabina
AU  - Tumino, Rosario
AU  - Sacerdote, Carlotta
AU  - Mattiello, Amalia
AU  - Onland-Moret, N Charlotte
AU  - Peeters, Petra H
AU  - Bueno-de-Mesquita, H B As
AU  - Weiderpass, Elisabete
AU  - Quirós, J Ramón
AU  - Duell, Eric J
AU  - Sánchez, Maria-Jose
AU  - Navarro, Carmen
AU  - Ardanaz, Eva
AU  - Larrañaga, Nerea
AU  - Nodin, Björn
AU  - Jirström, Karin
AU  - Idahl, Annika
AU  - Lundin, Eva
AU  - Khaw, Kay-Tee
AU  - Travis, Ruth C
AU  - Gunter, Marc
AU  - Johansson, Mattias
AU  - Dossus, Laure
AU  - Merritt, Melissa A
AU  - Riboli, Elio
AU  - Terry, Kathryn L
AU  - Cramer, Daniel W
AU  - Kaaks, Rudolf
TI  - Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
JO  - International journal of cancer
VL  - 142
IS  - 7
SN  - 0020-7136
CY  - Bognor Regis
PB  - Wiley-Liss
M1  - DKFZ-2018-00158
SP  - 1355 - 1360
PY  - 2018
AB  - CA125 is the best ovarian cancer early detection marker to date; however, sensitivity is limited and complementary markers are required to improve discrimination between ovarian cancer cases and non-cases. Anti-CA125 autoantibodies are observed in circulation. Our objective was to evaluate whether these antibodies (1) can serve as early detection markers, providing evidence of an immune response to a developing tumor, and (2) modify the discriminatory capacity of CA125 by either masking CA125 levels (resulting in lower discrimination) or acting synergistically to improve discrimination between cases and non-cases. We investigated these objectives using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition cohort (EPIC) including 250 cases diagnosed within 4 years of blood collection and up to four matched controls. Circulating CA125 antigen and antibody levels were quantified using an electrochemiluminescence assay. Adjusted areas under the curve (aAUCs) by 2-year lag-time intervals were calculated using conditional logistic regression calibrated toward the absolute risk estimates from a pre-existing epidemiological risk model as an offset-variable. Anti-CA125 levels alone did not discriminate cases from controls. For cases diagnosed <2 years after blood collection, discrimination by CA125 antigen was suggestively higher with higher anti-CA125 levels (aAUC, highest antibody tertile: 0.84 [0.76-0.92]; lowest tertile: 0.76 [0.67-0.86]; phet = 0.06). We provide the first evidence of potentially synergistic discrimination effects of CA125 and anti-CA125 antibodies in ovarian early detection. If these findings are replicated, evaluating CA125 in the context of its antibody may improve ovarian cancer early detection.
LB  - PUB:(DE-HGF)16
C6  - pmid:29159934
C2  - pmc:PMC5805613
DO  - DOI:10.1002/ijc.31164
UR  - https://inrepo02.dkfz.de/record/132470
ER  -